MX356801B - Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona. - Google Patents

Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.

Info

Publication number
MX356801B
MX356801B MX2013006071A MX2013006071A MX356801B MX 356801 B MX356801 B MX 356801B MX 2013006071 A MX2013006071 A MX 2013006071A MX 2013006071 A MX2013006071 A MX 2013006071A MX 356801 B MX356801 B MX 356801B
Authority
MX
Mexico
Prior art keywords
drug bioavailability
increasing drug
naltrexone therapy
naltrexone
therapy
Prior art date
Application number
MX2013006071A
Other languages
English (en)
Spanish (es)
Other versions
MX2013006071A (es
Inventor
Eduardo Dunayevich
Shawn Flanagan
Original Assignee
Orexigen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX356801(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orexigen Therapeutics Inc filed Critical Orexigen Therapeutics Inc
Publication of MX2013006071A publication Critical patent/MX2013006071A/es
Publication of MX356801B publication Critical patent/MX356801B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Acoustics & Sound (AREA)
  • Physics & Mathematics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
MX2013006071A 2010-12-03 2011-12-02 Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona. MX356801B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41939510P 2010-12-03 2010-12-03
PCT/US2011/063177 WO2012075459A1 (en) 2010-12-03 2011-12-02 Increasing drug bioavailability in naltrexone therapy

Publications (2)

Publication Number Publication Date
MX2013006071A MX2013006071A (es) 2013-10-01
MX356801B true MX356801B (es) 2018-06-13

Family

ID=46172304

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2013006071A MX356801B (es) 2010-12-03 2011-12-02 Incremento en la biodisponibilidad de fármacos en la terapia con naltrexona.
MX2017013169A MX384662B (es) 2010-12-03 2011-12-02 Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2017013169A MX384662B (es) 2010-12-03 2011-12-02 Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona

Country Status (27)

Country Link
US (1) US20130245056A1 (enExample)
EP (4) EP2646031B9 (enExample)
JP (5) JP6008866B2 (enExample)
KR (5) KR102391511B1 (enExample)
CN (1) CN103313711A (enExample)
AR (2) AR093182A1 (enExample)
AU (2) AU2011336304B2 (enExample)
BR (1) BR112013013390A2 (enExample)
CA (2) CA2819262C (enExample)
CL (1) CL2013001564A1 (enExample)
CY (2) CY1118968T1 (enExample)
DK (4) DK4349369T3 (enExample)
ES (2) ES2866879T3 (enExample)
FI (2) FI4349369T3 (enExample)
HR (3) HRP20240115T1 (enExample)
HU (3) HUE034393T2 (enExample)
IL (3) IL226504B (enExample)
LT (4) LT3884947T (enExample)
MX (2) MX356801B (enExample)
PL (3) PL2646031T3 (enExample)
PT (4) PT3884947T (enExample)
RS (3) RS62149B1 (enExample)
RU (1) RU2640561C2 (enExample)
SI (3) SI3884947T1 (enExample)
SM (4) SMT202400038T1 (enExample)
TW (1) TWI618536B (enExample)
WO (1) WO2012075459A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
MX383154B (es) 2010-01-11 2025-03-13 Nalpropion Pharmaceuticals Llc Usos de naltrexona y bupoprion para tratar depresión mayor.
PL2646031T3 (pl) * 2010-12-03 2017-08-31 Orexigen Therapeutics, Inc. Wzrost biodostępności leku w terapii naltreksonem
KR20220042241A (ko) 2012-06-06 2022-04-04 오렉시젠 세러퓨틱스 인크. 과체중 및 비만의 치료 방법
US20180015042A1 (en) * 2015-02-07 2018-01-18 Intas Pharmaceuticals Ltd. Pharmaceutical composition for the treatment of obesity
EP3600433B1 (en) * 2017-03-28 2021-05-05 LDN Pharma Limited An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) * 2017-11-14 2019-05-15 LDN Pharma Limited Cancer treatment
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10129265A1 (de) * 2001-06-18 2003-01-02 Hf Arzneimittelforsch Gmbh Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) * 2002-07-02 2005-12-06 Bernstein Richard K Method for reducing food intake
EP1772147A2 (en) * 2003-03-17 2007-04-11 Japan Tobacco, Inc. Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
EP1617832B1 (en) 2003-04-29 2008-03-12 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
WO2007016108A1 (en) 2005-07-27 2007-02-08 Orexigen Therapeutics, Inc. Compositions for affecting weight loss
US8921344B2 (en) * 2006-11-03 2014-12-30 Salix Pharmaceuticals, Inc. Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
EP3132792B1 (en) 2005-11-22 2019-09-11 Nalpropion Pharmaceuticals, Inc. Composition and methods for increasing insulin sensitivity
WO2007089318A2 (en) * 2005-11-23 2007-08-09 Orexigen Therapeutics, Inc. Compositions and methods for reducing food cravings
JP2009517393A (ja) 2005-11-28 2009-04-30 オレキシジェン・セラピューティクス・インコーポレーテッド 不安症の治療方法
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
EP2719378B1 (en) * 2006-06-19 2016-08-31 Alpharma Pharmaceuticals LLC Pharmaceutical compositions
KR101264789B1 (ko) * 2006-06-30 2013-05-15 엘지디스플레이 주식회사 횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) * 2006-07-20 2008-01-24 Somaxon Pharmaceuticals, Inc. Methods of improving the pharmacokinetics of doxepin
CN101573103A (zh) * 2006-11-09 2009-11-04 奥雷西根治疗公司 用于施用重量减轻药物的单位剂量包装和方法
CN101588795A (zh) 2006-11-09 2009-11-25 奥雷西根治疗公司 包含中间快速溶解层的分层药物制剂
DK2139485T3 (da) * 2007-04-11 2013-01-21 Biomarin Pharm Inc Fremgangsmåder til admistration af tetrahydrobiopterin, associerede sammensætninger, og fremgangsmåder til måling
DE102007036076A1 (de) 2007-08-01 2009-02-05 Bayer Healthcare Aktiengesellschaft Dipeptoid-Produgs und ihre Verwendung
US8318813B2 (en) * 2007-09-13 2012-11-27 Lcs Group, Llc Method of treating binge eating disorder
WO2009158114A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
PL2646031T3 (pl) 2010-12-03 2017-08-31 Orexigen Therapeutics, Inc. Wzrost biodostępności leku w terapii naltreksonem

Also Published As

Publication number Publication date
SMT202400038T1 (it) 2024-03-13
PT2646031T (pt) 2017-05-25
SMT202100227T1 (it) 2021-07-12
RU2017144631A (ru) 2019-02-18
RS62149B1 (sr) 2021-08-31
LT3222280T (lt) 2021-05-10
AU2017204309A1 (en) 2017-07-13
PL3884947T3 (pl) 2024-05-06
KR20210063473A (ko) 2021-06-01
RS65198B1 (sr) 2024-03-29
EP2646031A1 (en) 2013-10-09
HRP20210618T1 (hr) 2021-09-17
DK3884947T3 (da) 2024-01-22
EP2646031B1 (en) 2017-02-22
KR102105857B1 (ko) 2020-05-04
BR112013013390A2 (pt) 2016-09-06
CA2819262A1 (en) 2012-06-07
RU2013127423A (ru) 2015-01-10
IL226504B (en) 2021-01-31
HUE034393T2 (en) 2018-02-28
IL270841A (en) 2020-01-30
JP2022060331A (ja) 2022-04-14
KR20180069089A (ko) 2018-06-22
CN103313711A (zh) 2013-09-18
TW201304780A (zh) 2013-02-01
CY1118968T1 (el) 2018-01-10
PL3222280T3 (pl) 2021-11-29
LT2646031T (lt) 2017-06-26
PT4349369T (pt) 2025-12-17
RU2640561C2 (ru) 2018-01-09
SI3884947T1 (sl) 2024-06-28
JP2019056004A (ja) 2019-04-11
IL279626A (en) 2021-03-01
SMT202500474T1 (it) 2026-01-12
RU2017144631A3 (enExample) 2021-04-13
PL2646031T3 (pl) 2017-08-31
RS56014B1 (sr) 2017-09-29
JP2013544290A (ja) 2013-12-12
LT3884947T (lt) 2024-03-12
PT3884947T (pt) 2024-02-16
FI4349369T3 (fi) 2025-12-17
FI3884947T3 (fi) 2024-01-30
ES2866879T3 (es) 2021-10-20
JP6456890B2 (ja) 2019-01-23
WO2012075459A1 (en) 2012-06-07
EP4349369B1 (en) 2025-09-17
JP2024071605A (ja) 2024-05-24
CY1124331T1 (el) 2022-07-22
HUE053831T2 (hu) 2021-07-28
JP2016210809A (ja) 2016-12-15
EP3222280A1 (en) 2017-09-27
JP6008866B2 (ja) 2016-10-19
ES2625527T3 (es) 2017-07-19
US20130245056A1 (en) 2013-09-19
CL2013001564A1 (es) 2014-05-02
TWI618536B (zh) 2018-03-21
HUE065852T2 (hu) 2024-06-28
CA3239386A1 (en) 2012-06-07
ES2625527T9 (es) 2018-09-25
EP3222280B1 (en) 2021-01-20
EP2646031B9 (en) 2018-01-10
KR20190058702A (ko) 2019-05-29
KR20200044158A (ko) 2020-04-28
KR101984500B1 (ko) 2019-05-31
AU2011336304A1 (en) 2013-07-11
KR20140035320A (ko) 2014-03-21
MX384662B (es) 2025-03-14
CA2819262C (en) 2024-05-28
DK3222280T3 (da) 2021-04-19
AR124500A2 (es) 2023-04-05
DK2646031T3 (en) 2017-05-22
PT3222280T (pt) 2021-04-22
SI2646031T1 (sl) 2017-07-31
MX2013006071A (es) 2013-10-01
SMT201700232T1 (it) 2017-07-18
EP4349369A2 (en) 2024-04-10
EP3884947B1 (en) 2023-11-15
EP3884947A1 (en) 2021-09-29
AR093182A1 (es) 2015-05-27
AU2011336304B2 (en) 2017-03-30
HRP20170734T1 (hr) 2017-08-11
JP7025319B2 (ja) 2022-02-24
DK4349369T3 (da) 2025-12-22
SI3222280T1 (sl) 2021-11-30
EP4349369A3 (en) 2024-05-15
HRP20240115T1 (hr) 2024-06-07
KR102258043B1 (ko) 2021-05-28
KR102391511B1 (ko) 2022-04-26
LT4349369T (lt) 2026-01-12
EP2646031A4 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
MX384662B (es) Incremento en la biodisponibilidad de farmacos en la terapia con naltrexona
IL220768A0 (en) Devices, methods and kits for forming tracts in tissue
EP2672888A1 (en) Wireless, implantable electro-encephalography system
AU2012209332A8 (en) Methods and compositions for preparing noribogaine from voacangine
WO2012134613A3 (en) Pyridyldiamido transition metal complexes, production and use thereof
MY170719A (en) Antibody-drug conjugates
EP2850059A4 (en) CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
IL225597A0 (en) Pharmaceutical preparation, methods of treatment and its uses
IN2015DN01480A (enExample)
MX364229B (es) Composiciones y metodos para tratar enfermedades cardiovasculares.
GB201106750D0 (en) Novel compounds
WO2013158208A9 (en) Multi-modal synchronization therapy
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
MY158261A (en) Pharmaceutical com[osition comprising a strontium salt, vitamin d and a cyclodextrin
EP3118031B8 (en) Inflation work station
MY168166A (en) Polymer and Composition Including Same, and Adhesive Composition
TW201144301A (en) Processes for preparing linezolid
SG2013072061A (en) Method for producing modified conjugated diene-based polymer, and method for producing polymer composition
MX2012007898A (es) Metodos para proveer terapia de perdida de peso en pacientes con depresion mayor.
IL220707A0 (en) 2,5,7-substituted oxazolopyrimidine derivatives
ZA201406381B (en) Levoisovalerylspiramycin i,ii,iii,and preparations,preparations methods and uses thereof
EP2900274B8 (en) Conjugate of a fragment of a cellular wall of a bacterium and a mucopolysaccharidic carrier, and uses in medicine thereof
IL227544B (en) (r)- Leoplomide, a method for its preparation and its medical uses
MX2012010317A (es) ß-HIDROXIALQUILAMIDAS, METODO PARA SU PRODUCCION Y SU USO.
EP2645255A4 (en) Program generating device, program generating program, and program generating method

Legal Events

Date Code Title Description
FG Grant or registration